Nehal N. Mehta, MD, PI of the VIP Trial of NB-UVB for Psoriasis, Joins our SAB

Intervale, New Hampshire – March 20, 2024: Cytokind, Inc, a hybrid medtech/drug discovery company at the forefront of utilizing light-based therapies to address the silent symptoms of multiple sclerosis, is delighted to announce the appointment of Dr. Nehal N. Mehta to its esteemed Science Advisory Board. Dr. Mehta, an accomplished healthcare innovator with over 20 years of experience in academic clinical care, brings a wealth of knowledge and expertise to the board.

Dr. Mehta currently serves as Adjunct Associate Professor of Medicine, attending cardiologist, and Director of Inflammatory Risk in Preventive Cardiology at the Hospital of the University of Pennsylvania. Additionally, he is an Adjunct Scholar at the Center for Clinical Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine. With a remarkable career that includes being an Inaugural Lasker Clinical Scholar and former tenured Senior Investigator at the NIH, Dr. Mehta is well-versed in leading clinical trials to test the impact of novel therapies on humans.

Dr. Nehal N. Mehta stated, “I am thrilled to contribute my expertise to Cytokind’s innovative approach to treating multiple sclerosis. The potential of phototherapy to address the symptoms of this complex disease is truly exciting, and I look forward to collaborating with the talented team at Cytokind to advance their groundbreaking work.”

John MacMahon, CEO of Cytokind Inc., shared his excitement about Dr. Mehta’s appointment, saying, “We are honored to welcome Dr. Nehal N. Mehta to our Science Advisory Board. His extensive experience in clinical care and research, particularly in the field of inflammatory risk and the benefits of NB-UVB. As the Principal Investigator of the VIP trials of NB-UVB and psoriasis, Dr. Mehta will be invaluable as we continue to translate NB-UVB from dermatology to neurology. His expertise will play a pivotal role in guiding our research to benefit patients worldwide.”

About Cytokind, Inc.: Cytokind, Inc. is a hybrid medical device/drug discovery company advancing a translational application of phototherapy from dermatology to neurology. With a focus on harnessing the power of light and innovative therapies, Cytokind, Inc. is dedicated to strengthening the human immune system and revolutionizing treatment approaches for individuals living with MS.

For more information, contact:

John MacMahon

Jmacmahon@cytokind.net

603 264 7751